microRNA Replacement Therapy
Management

Mirna has assembled an experienced management team with leaders in microRNA and cancer research, and all aspects of drug and business development.

Mirna-Michael Powell
Dr. Paul Lammers has served as a member of Mirna’s board of directors and as President and Chief Executive Officer since November 2009. Previously, Dr. Lammers was the President of Repros Therapeutics Inc., a biopharmaceutical company. Dr. Lammers has also served as the Chief Medical Officer for EMD Serono, Inc., a biopharmaceutical division of Merck KGaA, Senior Vice President of clinical and regulatory affairs at Zonagen, Inc., which later became Repros Therapeutics, and Organon International, a pharmaceutical company, spending eight years in the commercial and clinical operations in Europe and the United States. Dr. Lammers received an M.Sc. and M.D. from the Catholic University (Radboud University) in Nijmegen, The Netherlands.
Mirna-Michael Powell
Alan Fuhrman has served as our Chief Financial Officer since September 2015. Mr. Fuhrman previously served as the Chief Financial Officer of Ambit Biosciences Corporation, a biopharmaceutical company, including through the company’s initial public offering in 2013 and until its sale to Daiichi Sankyo for up to $410 million. Prior to this role, Mr. Fuhrman served as Chief Financial Officer of Naviscan, Inc., a privately held medical imaging company and as Chief Financial Officer of Sonus Pharmaceuticals, Inc., a pharmaceutical company. Mr. Fuhrman is a member of the board of directors of Loxo Oncology, Inc. Earlier in Mr. Fuhrman’s career he practiced as a CPA with Coopers and Lybrand. Mr. Fuhrman received a B.S. in both Business Administration and Agricultural Economics from Montana State University.
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.